Infinity Develops Agent for Advanced Solid Tumors

Infinity Pharmaceuticals has started a Phase I clinical trial of IPI-493, its oral anti-chaperone agent, in patients with advanced solid tumors.

In preclinical studies, the agent has demonstrated oral availability and potent inhibition of heat shock protein 90 (Hsp90), a molecular chaperone that supports and stabilizes numerous cancer-causing proteins. Inhibiting Hsp90 can lead to the death of cancer cells, Infinity said.

The multicenter, dose-escalation study will assess the safety and tolerability of the agent and identify its treatment regimen.